BioGend Therapeutics Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 9.57 million compared to TWD 2.02 million a year ago. Net loss was TWD 52.04 million compared to TWD 39.24 million a year ago. Basic loss per share from continuing operations was TWD 0.5 compared to TWD 0.39 a year ago. Diluted loss per share from continuing operations was TWD 0.5 compared to TWD 0.39 a year ago.
For the nine months, sales was TWD 20.45 million compared to TWD 4.46 million a year ago. Net loss was TWD 131.14 million compared to TWD 124.34 million a year ago. Basic loss per share from continuing operations was TWD 1.27 compared to TWD 1.23 a year ago. Diluted loss per share from continuing operations was TWD 1.27 compared to TWD 1.23 a year ago.